505 related articles for article (PubMed ID: 34972975)
1. Immune Checkpoint Inhibitor (ICI)-Related Cardiotoxicity.
Zarifa A; Lopez-Mattei J; Palaskas NL; Iliescu C; Durand JB; Kim PY
Adv Exp Med Biol; 2021; 1342():377-387. PubMed ID: 34972975
[TBL] [Abstract][Full Text] [Related]
2. Immune Checkpoint Inhibitors (ICIs)-Related Cardiotoxicity.
Zarifa A; Lopez-Mattei J; Palaskas N; Iliescu C; Durand JB; Kim PY
Adv Exp Med Biol; 2020; 1244():277-285. PubMed ID: 32301022
[TBL] [Abstract][Full Text] [Related]
3. Cardiotoxicity of Immune Checkpoint Inhibitors.
Patel RP; Parikh R; Gunturu KS; Tariq RZ; Dani SS; Ganatra S; Nohria A
Curr Oncol Rep; 2021 May; 23(7):79. PubMed ID: 33937956
[TBL] [Abstract][Full Text] [Related]
4. Cardiotoxicities associated with immune checkpoint inhibitors.
Yang S; Asnani A
Curr Probl Cancer; 2018 Jul; 42(4):422-432. PubMed ID: 30173878
[TBL] [Abstract][Full Text] [Related]
5. Immune Checkpoint Inhibitor Cardiotoxicity: Understanding Basic Mechanisms and Clinical Characteristics and Finding a Cure.
Waliany S; Lee D; Witteles RM; Neal JW; Nguyen P; Davis MM; Salem JE; Wu SM; Moslehi JJ; Zhu H
Annu Rev Pharmacol Toxicol; 2021 Jan; 61():113-134. PubMed ID: 32776859
[TBL] [Abstract][Full Text] [Related]
6. Immune checkpoint inhibitor cardiotoxicity: Breaking barriers in the cardiovascular immune landscape.
Zhu H; Ivanovic M; Nguyen A; Nguyen PK; Wu SM
J Mol Cell Cardiol; 2021 Nov; 160():121-127. PubMed ID: 34303670
[TBL] [Abstract][Full Text] [Related]
7. Challenges and solutions in management of cardiotoxicity induced by checkpoint inhibitors.
Mladosievičová B; Országhová Z; Jablonická M; Rečková M; Chovanec M; Mego M
Klin Onkol; 2020; 33(5):350-355. PubMed ID: 33108879
[TBL] [Abstract][Full Text] [Related]
8. Immunotherapy-Associated Cardiotoxicity of Immune Checkpoint Inhibitors and Chimeric Antigen Receptor T Cell Therapy: Diagnostic and Management Challenges and Strategies.
Stein-Merlob AF; Rothberg MV; Holman P; Yang EH
Curr Cardiol Rep; 2021 Jan; 23(3):11. PubMed ID: 33483873
[TBL] [Abstract][Full Text] [Related]
9. Cardiotoxicity of immune checkpoint inhibitors: An updated review.
Behravesh S; Shomali N; Danbaran GR; Aslani S; Hemmatzadeh M; Hosseinzadeh R; Gowhari-Shabgah A; Mohammadi H
Biotechnol Appl Biochem; 2022 Feb; 69(1):61-69. PubMed ID: 33289168
[TBL] [Abstract][Full Text] [Related]
10. New Insights into Mechanisms of Immune Checkpoint Inhibitor-Induced Cardiovascular Toxicity.
Khunger A; Battel L; Wadhawan A; More A; Kapoor A; Agrawal N
Curr Oncol Rep; 2020 Jun; 22(7):65. PubMed ID: 32514647
[TBL] [Abstract][Full Text] [Related]
11. Cardiotoxicities of novel cancer immunotherapies.
Stein-Merlob AF; Rothberg MV; Ribas A; Yang EH
Heart; 2021 Nov; 107(21):1694-1703. PubMed ID: 33722826
[TBL] [Abstract][Full Text] [Related]
12. [Research Progress of Immune Checkpoint Inhibitor-associated Myocarditis].
Liu Y; Chen Y; Zeng Z; Liu A
Zhongguo Fei Ai Za Zhi; 2021 Sep; 24(9):668-672. PubMed ID: 34521189
[TBL] [Abstract][Full Text] [Related]
13. Emerging role of immune checkpoint inhibitors and their relevance for the cardiovascular system.
Michel L; Totzeck M; Lehmann L; Finke D
Herz; 2020 Nov; 45(7):645-651. PubMed ID: 32533218
[TBL] [Abstract][Full Text] [Related]
14. Cardiovascular toxicities associated with immune checkpoint inhibitors: an observational, retrospective, pharmacovigilance study.
Salem JE; Manouchehri A; Moey M; Lebrun-Vignes B; Bastarache L; Pariente A; Gobert A; Spano JP; Balko JM; Bonaca MP; Roden DM; Johnson DB; Moslehi JJ
Lancet Oncol; 2018 Dec; 19(12):1579-1589. PubMed ID: 30442497
[TBL] [Abstract][Full Text] [Related]
15. Pathophysiology, diagnosis and management of cardiac toxicity induced by immune checkpoint inhibitors and BRAF and MEK inhibitors.
Arangalage D; Degrauwe N; Michielin O; Monney P; Özdemir BC
Cancer Treat Rev; 2021 Nov; 100():102282. PubMed ID: 34438238
[TBL] [Abstract][Full Text] [Related]
16. Cardiotoxicity of immune checkpoint inhibitors: A systematic review and meta-analysis of randomised clinical trials.
Agostinetto E; Eiger D; Lambertini M; Ceppi M; Bruzzone M; Pondé N; Plummer C; Awada AH; Santoro A; Piccart-Gebhart M; de Azambuja E
Eur J Cancer; 2021 May; 148():76-91. PubMed ID: 33740500
[TBL] [Abstract][Full Text] [Related]
17. [Cardiotoxicity of immune checkpoint inhibitors used in cancer treatment].
Arangalage D; Pavon AG; Hugelshofer S; Desgraz B; Tzimas G; Delyon J; Muller O; Obeid M; Ribi C; Michielin O; Özdemir BC; Monney P
Rev Med Suisse; 2020 Jun; 16(696):1165-1168. PubMed ID: 32496706
[TBL] [Abstract][Full Text] [Related]
18. Immune checkpoint inhibitors - the revolutionary cancer immunotherapy comes with a cardiotoxic price.
Achim A; Liblik K; Gevaert S
Trends Cardiovasc Med; 2024 Feb; 34(2):71-77. PubMed ID: 36152788
[TBL] [Abstract][Full Text] [Related]
19. An Emergent Form of Cardiotoxicity: Acute Myocarditis Induced by Immune Checkpoint Inhibitors.
Esposito R; Fedele T; Orefice S; Cuomo V; Prastaro M; Canonico ME; Ilardi F; De Stefano F; Fiorillo L; Santoro C; Esposito G
Biomolecules; 2021 May; 11(6):. PubMed ID: 34067474
[TBL] [Abstract][Full Text] [Related]
20. Cardiovascular toxicity of immune checkpoint inhibitors in cancer patients: A review when cardiology meets immuno-oncology.
Chen DY; Huang WK; Chien-Chia Wu V; Chang WC; Chen JS; Chuang CK; Chu PH
J Formos Med Assoc; 2020 Oct; 119(10):1461-1475. PubMed ID: 31444018
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
